4//SEC Filing
Sukhtian Ghiath M. 4
Accession 0000947871-21-000128
CIK 0001649989other
Filed
Feb 1, 7:00 PM ET
Accepted
Feb 2, 5:32 PM ET
Size
10.2 KB
Accession
0000947871-21-000128
Insider Transaction Report
Form 4
GMS Ventures & Investments
Director10% Owner
Transactions
- Purchase
Common Stock
2021-02-02$1.00/sh+8,360,000$8,360,000→ 10,820,630 total(indirect: See Footnotes)
Holdings
- 21,606,437(indirect: See Footnotes)
Common Stock
Sukhtian Ghiath M.
Director10% Owner
Transactions
- Purchase
Common Stock
2021-02-02$1.00/sh+8,360,000$8,360,000→ 10,820,630 total(indirect: See Footnotes)
Holdings
- 21,606,437(indirect: See Footnotes)
Common Stock
Footnotes (4)
- [F1]These securities are held of record by GMS Ventures and Investments ("GMS Ventures"). Ghiath M. Sukhtian ("Ghiath Sukhtian"), a natural person, is the holder of a controlling interest in GMS Ventures. GMS Ventures has designated one representative to serve on the Issuer's board of directors. Therefore, GMS Ventures and Ghiath Sukhtian may be deemed a director by deputization.
- [F2]By virtue of the relationships described above in Footnote 1, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by GMS Ventures noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The Reporting Persons disclaim beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of its or his pecuniary interest therein, if any. This report shall not be deemed an admission that any of the Reporting Persons are the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
- [F3]These securities are held of record by BioLexis Pte Ltd. ("BioLexis"). Tenshi Life Sciences Private Limited ("Tenshi"), a private investment vehicle controlled by Arun Kumar Pillai ("Kumar"), and GMS Pharma (Singapore) Pte. Limited ("GMS Pharma"), a private investment company and wholly-owned subsidiary of GMS Holdings, are the 50:50 beneficial owners of BioLexis, in which each of Tenshi and GMS Pharma owns 50% of the outstanding voting shares. Kumar, a natural person, is the holder of a controlling interest in Tenshi. Ghiath Sukhtian is the holder of a controlling interest in GMS Holdings, which is the holder of a controlling interest in GMS Pharma.
- [F4]By virtue of the relationships described above in Footnote 3, Ghiath Sukhtian may be deemed to have voting and investment power with respect to the securities held by BioLexis noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Exchange Act. Ghiath Sukhtian disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Exchange Act, except to the extent of his pecuniary interest therein, if any. BioLexis has designated four representatives to serve on the Issuer's board of directors. This report shall not be deemed an admission that Ghiath Sukhtian is the beneficial owner of such securities for the purpose of Section 16 of the Exchange Act, or for any other purpose.
Documents
Issuer
Outlook Therapeutics, Inc.
CIK 0001649989
Entity typeother
Related Parties
1- filerCIK 0001717441
Filing Metadata
- Form type
- 4
- Filed
- Feb 1, 7:00 PM ET
- Accepted
- Feb 2, 5:32 PM ET
- Size
- 10.2 KB